ROLE OF IRON IN PARKINSON'S DISEASE
|Full paper||Not Available|
This study was carried out to evaluate the role of iron in the pathogenesis of Parkinson's disease (PD) and to deterimine the role of bromocriptine on iron concentration in PD patient serum as well as midbrain of experimental animals. Results of the present work revealed that there was non significant changes in serum iron level P>0.05, either in PD patient or in PD patients under bromocriptine treatment. In experimental animals, desferrioxamine (10 mg/ kg/LP. / day for 15 days) signcantly reduce midbrain iron level (P<0.05) while bromocriptirte (1.4 mg/kg/ oral day for 15 days) non significantly affect iron level (P>0.05). In addition, induction of PD in rats by single dose of fLuphenazine (10 mg/kg/S. C.) significantly elevate the midbrain iron concentration, P<0.05. and in PD rats treated with desferrioxamine there was significant reduction of midbrain iron level. P<0.05, but in PD rats treated with bromocriptine, there was non significant change in midbrain iron level, P>0.05. Moreover, concomitant administration of desferrioxamine (10 mg/kg/LP), bromocriptine (1.4 mg/Ica oral) with a single dose of fluphenazine (10 mg/kg/S.C.). there was significant reduction P<0.05 of iron in the tested brain area, so, it can be concluded that increased midbrain iron may participate in the development of PD. Moreover, bromocrip tine not affect iron concentration in midbrain, and desferrioxamine may be of a great value in the prophylaxis as well as the management of P.D.